Pulmonary Hypertension in Patients with Left Heart Disease: The Relationship with Left Ventricular Systolic Function

2013 ◽  
Vol 19 (10) ◽  
pp. S145-S146
Author(s):  
Tatsuro Ibe ◽  
Hiroshi Wada ◽  
Kenichi Sakakura ◽  
Nahoko Ikeda ◽  
Yoshitaka Sugawara ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Systolic Function ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Left Heart ◽  
Ventricular Systolic Function ◽  
Left Heart Disease ◽  
The Relationship

scholarly journals Under pressure: pulmonary hypertension associated with left heart disease

2015 ◽  
Vol 24 (138) ◽  
pp. 665-673 ◽  
Author(s):  
Harrison W. Farber ◽  
Simon Gibbs
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Survival Rates ◽  
Left Ventricular ◽  
Left Heart ◽  
Mean Pulmonary Arterial Pressure ◽  
Left Heart Disease ◽  
Right Heart Catheterisation ◽  
Pulmonary Capillary ◽  
Pulmonary Arterial

Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood. PH-LHD is diagnosed by right heart catheterisation with a mean pulmonary arterial pressure ≥25 mmHg and a pulmonary capillary wedge pressure >15 mmHg. The primary causes of PH-LHD are left ventricular dysfunction of systolic and diastolic origin, and valvular disease. Prognosis is poor and survival rates are low. Limited progress has been made towards specific therapies for PH-LHD, and management focuses on addressing the underlying cause of the disease with supportive therapies, surgery and pharmacological treatments. Clinical trials of therapies for pulmonary arterial hypertension in patients with PH-LHD have thus far been limited and have provided disappointing or conflicting results. Robust, long-term clinical studies in appropriate target populations have the potential to improve the outlook for patients with PH-LHD. Herein, we discuss the knowledge gaps in our understanding of PH-LHD, and describe the current unmet needs and challenges that are faced by clinicians when identifying and managing patients with this disease.

Clinical Application of Information Medicine Cardiac Magnetic Resonance Quantitative Imaging in Central Nervous System Cardiology Cardiomyopathy

2021 ◽  
Vol 11 (2) ◽  
pp. 623-629
Author(s):  
Jianhong Shen ◽  
Zanfei Li ◽  
Xianliang Ren
Keyword(s):  
Central Nervous System ◽  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Systolic Function ◽  
Quantitative Imaging ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Diffuse Fibrosis ◽  
Ventricular Systolic Function ◽  
The Relationship

Objective: To study the left ventricular systolic function in patients with central nervous system endocarditis myocarditis by using information-based cardiac magnetic resonance quantitative imaging technique. LGE and T1 mapping techniques were used to evaluate myocardial localized fibrosis and diffuse fibrosis, respectively. The situation is to explore the limitations and the relationship between diffuse cardiomyopathy and cardiac function. Methods: A total of 44 patients with dilated cardiomyopathy and 23 healthy volunteers were scanned with a magnetic resonance imager to determine the occurrence of focal myocardial and diffuse fibrosis, and to analyze the relationship between left ventricular systolic function and left ventricular systolic function. Relationship. Results: The TML values (1335.23 ± 60.91 ms) and LGE (–) subgroups (1309.05 ± 55.02 ms) in the DCMLGE(+) subgroup were significantly different from those in the control group (P < 0.001); however, DCMLGE ( There was no significant difference in the myocardial T1 values between the + and LGE (–) groups (P > 0.05). Conclusion: Cardiac magnetic resonance quantitative imaging technology can reflect the diffuse fibrosis of patients with cardiomyopathy, and can detect early myocardial fibrosis early. In addition, patients with cardiomyopathy have myocardial limitations and diffuse fibrosis, which affects the contractile function of the left ventricle of the heart.

scholarly journals Pulmonary Hypertension Due to Left Heart Disease

2016 ◽  
Vol 01 (03) ◽  
pp. 016-019
Author(s):  
S. Basha ◽  
G. Deepthi
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Diastolic Pressure ◽  
General Scheme ◽  
Left Ventricular ◽  
Left Heart ◽  
Mean Pulmonary Arterial Pressure ◽  
Left Heart Disease ◽  
Pulmonary Capillary ◽  
Group 2

AbstractThe most common cause of pulmonary hypertension is left heart disease, arising in response to increased left ventricular or left a trial filling pressures[1,2,3]. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications, placing the Pulmonary Hypertension due to left heart disease in Group 2 [4]. PH is defined by a mean pulmonary arterial pressure >25 mmHg. In the case of PH associated with LHD, this is associated with a pulmonary capillary wedge pressure >15 mmHg or left ventricular end-diastolic pressure (LVEDP) > 18 mm Hg [1,5]. Pulmonary hypertension due to left-sided heart disease is associated with higher morbidity and mortality [6,7,8]. This study is done to know the pattern of clinical presentation of pulmonary hypertension and to see the gender difference.

Sign in / Sign up

Export Citation Format

Share Document